Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 5 Issue 2

Immediate Hypersensitivity Reaction Following Patch Test to Celecoxib

Syrine Ben-Hammamia*, Ahmed Zaiem, Sihem El-Aidli and Riadh Daghfous

Adverse events collection and analysis department, National Center of Pharmacovigilance, Medicine faculty, Tunis, Tunisia

*Corresponding Author: Syrine Ben-Hammamia, Adverse events collection and analysis department, National Center of Pharmacovigilance, Medicine faculty, Tunis, Tunisia.

Received: November 30, 2020; Published: January 11, 2021



Patch-tests (PT) are usually safe. Complications are quite rare, and immediate anaphylactoid reactions are exceptional We report a case of a 38-year-old woman, who presented late toxidermia after celecoxib use, and then was explored by PT three months later. This PT was performed with celecoxib diluted to 30%. The patient developed twenty minutes later general itchy erythema, which regressed in an hour, under anti-histamine treatment. This case leads to reconsider possible immediate complications after PT and therefore increase vigilance for at least 30 minutes after patchingPT: Punch Tool; VSS: Vancouver Scar Scale; PDO: Polydioxanone.

Keywords: Patch Test; Immediate Hypersensitivity Reaction; Celecoxib



  1. Arimone Y., et al. “Updating the French Method for the Causality Assessment of Adverse Drug Reactions”. Thérapie2 (2013): 69-76.
  2. Roll A., et al. “Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs”. Swiss Medical Weekly 136 (2006): 684-690.
  3. Andria L., et al. “Safety of Celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance”. Allergology Immunopathology4 (2007): 126-129.
  4. Schmutz JL., et al. “Toxic epidermal necrolysis and celecoxib (Celebrex)”. Annales de Dermatologie et de Vénéréologie 131 (2004): 107.
  5. Yukiyasu A., et al. “Celecoxib-induced erythema multiforme-type drug eruption with a positive patch test”. Journal of Dermatology12 (2011): 1185-1188.
  6. Lee SK., et al. “Acute generalized exanthematous pustulosis induced by celecoxib”. Journal of Cutaneous Pathology 1 (2016): 80-81.
  7. Eui HO. “Drug-induced bullous Sweet's syndrome by celecoxib”. Journal of Dermatology9 (2016): 1092-1093.
  8. Levy M B., et al. “Anaphylaxis to celecoxib”. Annals of Allergy, Asthma and Immunology 1 (2001): 72-73.
  9. Stingeni L., et al. “Skin tests in the diagnosis of adverse drug reactions: a systematic review”. Giornale Italiano di Dermatologia e Venereologia (2020).
  10. Castelain M. “Effets secondaires, complications et contre-indications des patch-tests”. Annales de Dermatologie et de Vénéréologie 136 (2009) :645-649.
  11. Janice K., et al. “How stress and anxiety can alter immediate and late phase skin test responses in allergic rhinitis”. Psychoneuroendocrinology 34 (2009): 670-680.
  12. Wolf R., et al. “Never perform patch tests in a patient on antihistamines-dispelling the myth”. Skinmed 5 (2005): 318-319.


Citation: Syrine Ben-Hammamia., et al. “Immediate Hypersensitivity Reaction Following Patch Test to Celecoxib”.Acta Scientific Medical Sciences 5.2 (2021): 11-13.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US